Department of General Surgery, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of General Surgery, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Med Res Rev. 2021 Jul;41(4):2474-2488. doi: 10.1002/med.21801. Epub 2021 Apr 10.
Pancreatitis is a common gastrointestinal disease with no effective therapeutic options, particularly for cases of severe acute and chronic pancreatitis (CP). Mesenchymal stromal cells (MSCs) are multipotent cells with diverse biological properties, including directional migration, paracrine, immunosuppressive, and antiinflammatory effects, which are considered an ideal candidate cell type for repairing tissue damage caused by various pathogenies. Several researchers have reported significant therapeutic efficacy of MSCs in animal models of acute and CP. However, the specific underlying mechanisms are yet to be clarified and clinical application of MSCs as pancreatitis therapy has rarely been reported. This review mainly focuses on the potential and challenges in clinical application of MSCs for treatment of acute and CP, along with discussion of the underlying molecular mechanisms.
胰腺炎是一种常见的胃肠道疾病，目前尚无有效的治疗方法，特别是对于重症急性和慢性胰腺炎（CP）。间充质基质细胞（MSCs）是一种多能细胞，具有多种生物学特性，包括定向迁移、旁分泌、免疫抑制和抗炎作用，被认为是修复各种病因引起的组织损伤的理想候选细胞类型。一些研究人员已经报道了 MSCs 在急性和 CP 动物模型中的显著治疗效果。然而，其具体的潜在机制尚不清楚，并且很少有关于 MSCs 作为胰腺炎治疗的临床应用的报道。本综述主要关注 MSCs 在治疗急性和 CP 中的临床应用的潜力和挑战，并讨论其潜在的分子机制。
